Maruti, IHCL, Godrej Consumer are among Jefferies' top picks

Maruti, IHCL, Godrej Consumer are among Jefferies' top picks
ET Bureau
Rate Story
Share
Font Size
Save
Comment
Synopsis

Jefferies said the company's margins could jump to 31-32% for FY24-25 against 13% in FY22. "During Covid, IHCL has deployed several measures to contain its fixed cost and prune variable costs, and some of these are likely to be permanent."

Agencies
The brokerage said Cipla will launch high-value products like gAdvair, gAbraxane in the second-half of FY23 and will ramp up its peptide injectable, which will lead to margin expansion during FY22-24.
Mumbai: Jefferies expects EBITDA (earnings before interest, taxes, depreciation and amortisation) margin - a popular measure of operational profitability - of companies that it tracks to rebound to 21.8% in FY24 from 20.8% estimated in FY23. In FY22, the EBITDA margin declined by 100 basis points to 21.6%. "Potential recession in the developed world depressing commodity prices can drive the (margin) upside," said the brokerage in a note to clients. ET looks at six picks that Jefferies has identified in the margin expansion theme.

Maruti Suzuki: The brokerage expects Maruti's EBITDA margin to improve from 6.5% in FY22 to 11.8% in FY24 with easing commodity prices and improving pricing power amid goDLF, od demand and new launches.

Indian Hotels: Jefferies said the company's margins could jump to 31-32% for FY24-25 against 13% in FY22. "During Covid, IHCL has deployed several measures to contain its fixed cost and prune variable costs, and some of these are likely to be permanent."

Godrej Consumer Products: After facing margin pressures in the past few quarters, the company's margins could improve to over 20% in the second-half of FY23 and FY24 as against 16% in the first quarter, the brokerage said.
DLF: The real estate firm's margin improvement is led by a jump in Gurgaon property prices and a mix improvement in revenue recognition, said Jefferies.

Cipla: The brokerage said will launch high-value products like gAdvair, gAbraxane in the second-half of FY23 and will ramp up its peptide injectable, which will lead to margin expansion during FY22-24.

Adani Ports: Jefferies said the company could see double-digit volume growth through market share gains. Operating leverage and cost optimisation at new ports will further help the margins, it said.

Experience Your Economic Times Newspaper, The Digital Way!

Read More News on

(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

...more
Pick the best stocks for yourself
Powered by
Read before you invest. Insights on Godrej Consumer Products Ltd.. Explore Now